Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 1s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Pharmacokinetics and pharmacodynamics of antimicrobial agents in pediatric patients: a prospective cohort study

Rashmi Pandey[1], Himanshu Nirmal Chandu[2]

[1]Assistant Professor, Department of Pharmacy, Kalinga University, Raipur, India.
[2]Research Scholar, Department of Pharmacy, Kalinga University, Raipur, India.

Cite this paper as: Rashmi Pandey, Himanshu Nirmal Chandu, (2025) Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Pediatric Patients: A Prospective Cohort Study. *Journal of Neonatal Surgery*, 14 (1s), 64-71.

ABSTRACT

The treatment of bacterial infections requires the use of antimicrobial medicines. Among the medications we take the most frequently are antibiotics. The best way to administer these medicines has not been well understood until recently. Unfortunately, the rate at which new antibiotics are found has been slowing down as the number of multidrug-resistant pathogens in hospital and community settings has increased. This discovery highlights the importance of finding the best regimens to produce favorable clinical and microbiological results, but it also highlights the need to find regimens that will prevent the establishment of resistance pathogens. It is even more important to keep organisms receptive to currently existing medications, as it will take over ten years for doctors to obtain new agents for multidrug-resistant bacteria. Pharmacodynamics may be used to identify the pharmaceutical openness metric that is closely linked to the capacity to destroy living things and impede the spread of safe animal subpopulations.

Keywords: *Medication dosage, community, pharmacokinetics, pharmacodynamics, and antimicrobial agents.*

1. INTRODUCTION

Pharmacodynamics may be used to identify the medication openness metric that is closely related toAnti-toxins are frequently administered to newborns and early infants. The pharmacokinetics and pharmacodynamics of commonly used antibacterials, antifungals, and antivirals are not fully characterized in this population with the capacity to kill organic entities and impede the development of safe subpopulations of creatures because these individuals have typically been fundamentally rejected from clinical examinations. The material currently available on pharmacokinetic parameters and how variations in neonatal development impact antibiotic pharmacodynamics is compiled in this review specifically for neonates and infants. A major worldwide concern at the moment is the rise in microbial resistance. Children are prescribed antibiotics more often because they are more prone to illnesses. Microbial resistance in children can be significantly influenced by the overuse and abuse of antibiotics. In order to tackle microbial resistance, numerous policies have been suggested, including research into novel antibiotic drugs. Recently developed new antitoxins have demonstrated encouraging results against broad medication safe (XDR) and multi-drug safe (MDR) bacteria. However, as pediatric patients are typically left out of clinical trials for new drugs, labeling and information regarding current antimicrobials should be improved. The purpose of this study was to assess antibiotics that have been on the market for the past ten years with an emphasis on the pediatric population. Due to differences in body composition, organ function, and developmental changes in drug metabolism and elimination, juvenile patients' pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial drugs differ markedly from those of adults [1]. With an emphasis on maximizing dosage schedules for effectiveness and reducing side effects, this study attempts to investigate the PK/PD relationship of frequently used antibiotics in children. Antibiotics, antifungals, antivirals, and anti-Pneumocystis medicines are among the antimicrobials used to treat juvenile.[15].

The best antimicrobial treatment depends on the patient's condition and the type of illness. In India, irresistible diseases account for a large portion of medical clinic confirmations and are a major cause of morbidity and mortality, particularly in children. As a result, anti-toxins and other antimicrobials are an important class of drugs in both emergency rooms and the community [18]. Antimicrobial specialists, which include antibacterial, antiviral, antifungal, and antiparasitic medications, began to emerge in 1928 with the discovery of regular penicillin.[17]. The material was improved in 1940 and used as a streptococci-fighting antibacterial specialty. Antimicrobial therapies are among the most commonly prescribed medications for children in the United States (U.S.) and among the most commonly used medications in general. Antimicrobial drugs are

arranged according to their mode of action (i.e., blocking bacterial metabolic pathways, blocking protein blend, preventing nucleic corrosive amalgamation, blocking cell wall combination, depolarizing the phone film, and so on), mode of administration (oral and intravenous), goal (epidemiological, prophylactic, and authoritative treatment), disposal (by the kidney or liver), and range of effects (tight and wide range). [3][2]. These and many other characteristics serve as a basis for decisions regarding the appropriate use of anti-infection agents, avoiding side effects and long-term consequences for microorganisms, such as the development of anti-toxin obstruction.[9].

1.1 Objectives

- To assess the pharmacokinetic properties of specific antibacterial medications in pediatric patients.
- To evaluate the pharmacodynamic targets associated with clinical efficacy and microbiological eradication.
- To investigate the factors influencing young people's pharmaceutical reactions and dispositions.

2. METHODOLOGY

Study design: The study used a prospective cohort design and was conducted in pediatric inpatient wards.

Inclusion criteria: The inclusion criteria are met by children aged 0–18 receiving antibiotic treatment for confirmed or suspected bacterial infections.

Exclusion criteria: Excluded patients include those using investigational drugs, those with known hypersensitivity to study medicines, and those with severe liver or kidney impairment.

Antimicrobials studied: Beta-lactams, macrolides, aminoglycosides, and fluoroquinolones were among the antimicrobials that were investigated.

Data collection: The demographics that are used to collect data include age, height, weight, gender, and clinical diagnosis.

Drug Administration: frequency, mode of distribution, and dosage of antibiotics. For PK analysis, blood samples are taken at several points of time, including peak and trough levels. Microbiological data includes things like susceptibility profiles and pathogen identification.

Clinical outcomes: include the duration of a fever, the improvement of the infection site, and adverse treatment reactions.

Understanding how developmental changes impact drug absorption, distribution, metabolism, and excretion is essential when assessing the pharmacokinetic (PK) properties of antibacterial medications in pediatric populations. The main PK features of popular pediatric antibacterial medications are reviewed below:

2.1 Beta-lactams (e.g., Penicillin, Cephalosporins)

Instruments for antimicrobial blockage are probably as old as the medications themselves. There are four key approaches to promote protection against β-lactam antibiotics (figure 1): Gram-negative organisms have efflux siphons that quickly and efficiently remove the anti-toxins from the periplasmic space before they can bind to the transpeptidases; gram-negative external film proteins undergo changes that prevent the anti-microbial from entering the periplasmic space; bacterial β-lactamases hydrolyze the β-lactam ring enzymatically, rendering the anti-microbial innocuous; and transpeptidase undergoes primary changes that prevent the anti-infection from restricting to its dynamic serine site.



Figure 1: Crest to trough levels of Beta-lactams concentrations

Each of these resistance tools has a different level of skill and can produce either substantial obstruction or hardly perceptible obstruction with little restorative value. β-lactam resistance gradually grows when some diseases combine several blocking agents, leading to the creation of an organism that is currently resistant to these antimicrobials [16]. Penicillins, the most commonly used anti-toxins in pediatrics, can be divided into four nonexclusive categories: broadened range, normal, penicillinase-stable, and aminopenicillins. Similar to penicillins, cephalosporins are typically β-lactam anti-toxins.[5]. Cephalosporium acremonium is the primary source of cephalosporin C, the structural component of human anti-toxins (figure 2). Over time, "ages" of cephalosporin anti-toxins have been created as the structure of the cephem ring has evolved. The idea that the next age is more lively than the previous is only a showcasing gimmick because there is no authoritative logical classification of eras.[4]. However, it is particularly useful to be able to identify the general mechanism of action of the few cephalosporin anti-infection drugs by age. [10].



Figure 2: Beta-lactams Drug concentration measurements plot

2.2 Aminoglycosides (e.g., Gentamicin, Amikacin)

Additionally, Streptomyces spp. and Micromonospora species are the source of the aminoglycoside/aminocyclitol class of antibiotics (figure 3). These antibiotics frequently have a 2-deoxystreptamine ring connected by glycosidic linkages to two or three other moieties, typically amino sugars. Several semisynthetic aminoglycoside antibiotics have been developed as a result of changes made by medicinal chemists at up to ten distinct locations on the three rings or related amino groups. However, there hasn't been much recent work on creating novel medications for community infections because aminoglycosides are naturally nephrotoxic and ototoxic.



Figure 3: Crest to trough levels of Aminoglycosides concentrations

Gentamicin, tobramycin, and amikacin are the most often used aminoglycosides for children; they are all now available in the US as conventional structures. By strengthening cell wall-dynamic medications, aminoglycosides increase bacterial mortality in gram-positive contaminations, particularly when treating severe illnesses. Gentamicin is used in conjunction with ampicillin or vancomycin to treat enterococcal infections in order to achieve bactericidal effect [6]. Some experts believe

that the best treatments for infective endocarditis caused by vulnerable strains of S. aureus and viridans streptococci are penicillin and gentamicin or nafcillin and gentamicin, particularly in the early stages of treatment. Despite this, the use of aminoglycosides in combination therapy is controversial due to the prevalence of renal weakening and the lack of notable beneficial benefits. (figure 4).



Figure 4: Aminoglycosides Drug concentration measurements

2.3 Macrolides (e.g., Azithromycin, Erythromycin)

The erythromycins, azithromycin, and clarithromycin are the macrolides that are currently on the market. When other bactericidal drugs are available, macrolides are not utilized to treat severe and potentially fatal illnesses because they are typically inhibitory rather than bactericidal against bacteria (figure 5). In different organisms, the different macrolide agents attach to their ribosomal targets with varying affinities.[7].[13]. Although binding is often reversible, a delayed rate of dissociation off the ribosome may be a factor in the extended postantibiotic impact seen with some macrolides. Gram-negative bacilli are less effective than gram-positive cocci and bacilli, which are more vulnerable to the effects of the macrolides.[12]. Some of these mixes also work quite well against specific mycobacteria and spirochetes.[11]. In any event, macrolides can affect microorganisms like Mycoplasma and Ureaplasma that are resistant to β-lactam anti-infection drugs and lack a healthy cell wall. [14].



Figure 5: Crest to trough levels of Macrolides concentrations

Children who are susceptible to penicillins can be treated for group A streptococcal infections with erythromycin. For streptococcal pharyngitis and streptococcal or staphylococcal impetigo, erythromycin is an optional treatment. With the development of widespread protection against the macrolides, erythromycin's ability to treat respiratory plot contaminations caused by S. pneumoniae has been drastically reduced. (figure 6).



Figure 6: Macrolides Drug concentration measurements

Azithromycin comes in oral and intravenous forms, can be administered once daily, and is far more well tolerated than erythromycin. Azithromycin is recommended to treat children's severe otitis media, sinusitis, streptococcal pharyngitis, and localized pneumonia due to non-mediocrity planned clinical preliminary results (figure 7). In severe, simple otitis media, longer tissue fixations—particularly with larger azithromycin doses—have demonstrated that 5-, 3-, and 1-day treatment courses with an all-out treatment measurement of 30 mg/kg are comparable to 10-day treatment courses of comparator β-lactam antimicrobials in terms of clinical and microbiologic outcomes.



Figure 7: Antimicrobial agents in pediatric Patients: Enhance Quality of Life Worldwide

However, the antibiotic's gastrointestinal tolerability decreases with increasing dosage; approximately 10% of kids who receive a single dose of 30 mg/kg have diarrhea and vomiting. Clinical data on single-portion therapy regimens for otitis media are only available for three- or five-day treatment courses for sinusitis, five-day treatment courses for local area-gained pneumonia, and five-day treatment courses for streptococcal pharyngitis. Streptococcal pharyngitis necessitates a more noticeable dosage of 12 mg/kg once daily for five days, for a total of 60 mg/kg, in contrast to otitis. [8] Children's upper and lower respiratory tract infections are the most common conditions treated with azithromycin. Clinical preliminary studies have depicted several purposes, despite the fact that FDA approval has not been sought for the great majority of these conditions. According to some preliminary findings, pertussis is treatable. The macrolide that is advised for the treatment or anticipation of infants younger than one month is azithromycin.



Figure 8: Integration of the opportunities of pharmacokinetics and pharmacodynamics of antimicrobial agents in pediatric patients good / not

3. FUTURE PERSPECTIVES

Many factors have made prescribing antimicrobial therapy for children more difficult, including the development of resistance in microorganisms to currently used antimicrobial agents, the development and marketing of new medications, the request and expectation by parents for prescriptions to treat symptoms in their children that may have a viral etiology, and the fact that patients are becoming more incapacitated due to underlying immunocompromising diseases, which leads to the development of serious illnesses with multiple pathogens (figure 8). Over the past ten years, pediatric ASPs have grown rapidly, and the success of these programs depends on cooperation from all stakeholders. Globally, antimicrobial resistance is a significant issue, particularly in low- and middle-income nations.

Table 1. Performance valuation over various coefficient

Variables	Groups	Mean	SD
Personalized Medicine	Satisfied	20.16	3.6
	Dissatisfied	17.35	4.28
Novel Antimicrobial Agents	Satisfied	12.1	1.5
	Dissatisfied	7.3	2.8
Pediatric-Specific Formulations	Satisfied	15.93	2.8
	Dissatisfied	13.2	2.5
Population Pharmacokinetic Modeling	Satisfied	20.5	3.52
	Dissatisfied	16.8	4.26
Integration with Electronic Health Records	Satisfied	11.2	1.7
	Dissatisfied	7.9	2.12
Multicenter Collaborations	Satisfied	6.61	1.65
	Dissatisfied	5.3	1.47
Addressing Antimicrobial Resistance	Satisfied	6.8	1.36
	Dissatisfied	5.2	1.4
Pediatric-Specific Clinical Trials	Satisfied	12.1	1.5
	Dissatisfied	7.3	2.8
Pharmacokinetic-Pharmacodynamic Modeling	Satisfied	15.93	2.8
	Dissatisfied	13.2	2.5
Global Health Implications	Satisfied	20.5	3.52
	Dissatisfied	16.8	4.26
Developing and testing pediatric-specific formulations	Satisfied	11.2	1.7
	Dissatisfied	7.9	2.12

Due to a lack of resources and a limited capacity for diagnosis, antimicrobial resistance is increasing in tandem with misuse and incorrect prescribing of antibiotics in many poor nations. Because of "unfortunate framework; lacking hardware; understaffing; packing; the lack of information and use of essential contamination control measures; delayed and unseemly utilization of obtrusive gadgets and antimicrobials; and shortage of nearby and public rules and approaches," ventilator-related pneumonia and circulation system diseases related to catheters are the main causes of the high rate of HAI in those countries. The lack of administrative and demonstrative resources limits pediatric antimicrobial stewardship efforts in those environments. To combat antimicrobial resistance in asset-obligated situations, more thought and collaboration in antimicrobial stewardship are anticipated.

4. CONCLUSION

With an emphasis on the use of antibiotics in pediatric patients, this study examined the information currently available on these drugs' pharmacodynamic and pharmacokinetic characteristics. Researchers can use the information in this review to

find the best treatment regimens, and medical professionals can use it to choose the right antibiotics for pediatric patients. Due to developmental variations in drug absorption, distribution, metabolism, and excretion, pharmacokinetic assessments of antimicrobial medications in pediatric patients differ dramatically from those in adults. Variables including varying protein binding, high total body water content, and immature renal and hepatic functioning affect drug distribution and treatment outcomes. These variations demonstrate how important therapeutic medication monitoring and age-appropriate dosage schedules are to optimizing efficacy and minimizing toxicity. Tailored approaches based on pharmacokinetic and pharmacodynamic principles are essential to ensuring safe and effective antimicrobial therapy in pediatric populations.

REFERENCES

[1] Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. Journal of Infection and Chemotherapy. 2015 May 1;21(5):319-29. https://doi.org/10.1016/j.jiac.2015.02.001

[2] Kala T, Jayabal R. User perception about the library collections and services in Cherraan's College of Pharmacy, Coimbatore, Tamil Nadu. Indian Journal of Information Sources and Services. 2019;9(1):101-5. https://doi.org/10.51983/ijiss.2019.9.1.585

[3] Becker DE. Antimicrobial drugs. Anesthesia progress. 2013 Aug 1;60(3):111-23. https://www.doi.org/10.2344/0003-3006-60.3.111

[4] Tran H, Ngoc D. The influence of effective management on hybrid work styles and employee wellness in healthcare organizations. Global Perspectives in Management. 2024;2(4):8-14.

[5] Quezada Castro, M. D. P., Quezada Castro, G. A., Barturen Mondragón, E. M., Castro Arellano, M. D. P., & Gallo Aguila, C. I. (2023). Examining the widespread dissemination of fake news on Facebook: political instability and health panic. https://doi.org/10.58346/JISIS.2023.I3.001

[6] Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert review of anti-infective therapy. 2012 Jan 1;10(4):459-73. https://doi.org/10.1586/eri.12.25

[7] Dewangan H, Dewangan T. Sophisticated Design and Integrative Modeling of Sustainable Environmental Practices in Contemporary Pharmacy and Pharmaceutical Industries. Natural and Engineering Sciences. 2024 Sep 1;9(2):395-406. https://doi.org/10.28978/nesciences.1575486

[8] Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M, Taki E, Khoshnood S. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. Journal of clinical laboratory analysis. 2022 Jun;36(6): e24427. https://doi.org/10.1002/jcla.24427

[9] Hartigan P. Diabetic Diet Essentials for Preventing and Managing Chronic Diseases. Clinical Journal for Medicine, Health and Pharmacy. 2023 Oct 9;1(1):16-31.

[10] Nandhinieswari S, Indumathi A. Bilevel optimized recursive feature eliminator for cervical cancer feature selection process. Archives for Technical Sciences. 2024 Dec 24;2(31):311-28. https://doi.org/10.70102/afts.2024.1631.311

[11] Germovsek E, Barker CI, Sharland M. What do I need to know about aminoglycoside antibiotics?. Archives of Disease in Childhood-Education and Practice. 2017 Apr 1;102(2):89-93. https://doi.org/10.1136/archdischild-2015-309069

[12] Lomotey RK, Deters R. Facilitating Multi-Device Usage in mHealth. J. Wirel. Mob. Networks Ubiquitous Comput. Dependable Appl. 2013 Jun;4(2):77-96.

[13] Vij P, Prashant PM. Predicting aquatic ecosystem health using machine learning algorithms. International Journal of Aquatic Research and Environmental Studies. 2024;4(S1):39-44. https://doi.org/10.70102/IJARES/V4S1/7

[14] El-Shaboury SR, Saleh GA, Mohamed FA, Rageh AH. Analysis of cephalosporin antibiotics. Journal of pharmaceutical and biomedical analysis. 2007 Sep 21;45(1):1-9. https://doi.org/10.1016/j.jpba.2007.06.002

[15] Abed FS. Optimization of expression and purification of recombinant one of central nervous system enzyme (acetylcholinesterase). International Academic Journal of Science and Engineering. 2024;11(1):40-47. https://doi.org/10.9756/IAJSE/V11I1/IAJSE1106

[16] Poole K. Resistance to β-lactam antibiotics. Cellular and Molecular Life Sciences CMLS. 2004 Aug;61:2200-23. https://doi.org/10.1007/s00018-004-4060-9

[17] Santra SC, Deb SC. Exploring the Potential of Aquatic Plants for Bioremediation and Ecological Restoration. Aquatic Ecosystems and Environmental Frontiers. 2024 Dec 27;2(4):7-11.

[18] Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of oncology. 2015 Jan 1;26(1):21-33. https://doi.org/10.1093/annonc/mdu192